Q32 Bio Inc
$ 3.20
0.00%
26 Dec - close price
- Market Cap 39,373,900 USD
- Current Price $ 3.20
- High / Low $ 3.25 / 3.06
- Stock P/E N/A
- Book Value -1.50
- EPS -3.40
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -4.92 %
- 52 Week High 4.15
- 52 Week Low 1.34
About
None
Analyst Target Price
$15.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-06 | 2025-05-07 | 2025-03-11 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-03-13 | 2023-11-14 | 2023-08-14 | 2023-05-11 | 2023-03-09 |
| Reported EPS | -0.6 | -0.78 | -0.9 | -1.16 | -1.457 | -1.42 | -14.95 | -0.28 | -0.57 | -0.61 | -0.5 | -10.8 |
| Estimated EPS | -1.19 | -0.8 | -1.23 | -1.53 | -1.4 | -1.04 | -2.32 | -0.3 | -0.43 | -0.5 | -0.52 | -0.4922 |
| Surprise | 0.59 | 0.02 | 0.33 | 0.37 | -0.057 | -0.38 | -12.63 | 0.02 | -0.14 | -0.11 | 0.02 | -10.3078 |
| Surprise Percentage | 49.5798% | 2.5% | 26.8293% | 24.183% | -4.0714% | -36.5385% | -544.3966% | 6.6667% | -32.5581% | -22% | 3.8462% | -2094.23% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QTTB
2025-12-19 21:09:10
Mark Iwicki has withdrawn his resignation from Q32 Bio Inc.'s board of directors and will continue as chairman, chair of the Compensation Committee, and a member of the Audit Committee. This decision followed a reduction in his other board commitments. The company recently sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics for upfront and milestone payments totaling up to $604 million, and Oppenheimer maintained an Outperform rating on Q32 Bio stock with a $20 price target.
2025-12-18 12:11:24
Oppenheimer has reiterated an Outperform rating and a $20.00 price target for Q32 Bio Inc. (NASDAQ:QTTB), citing a "favorable read-through" from a competitor's recent clinical trial in alopecia areata despite its technical failure. This target represents a significant upside, and the company is also pursuing strategic initiatives, including the sale of a Phase 2 complement inhibitor to Akebia Therapeutics for substantial upfront and milestone payments.
2025-12-07 18:09:23
Insiders at Q32 Bio Inc. (NASDAQ:QTTB) sold shares earlier this year at US$2.86, potentially missing out on recent stock gains that saw the price rise by 52%. While the recent sale by Jodie Morrison was the largest insider sale in the last year, there have been no insider purchases, making investors cautious. The total insider shareholding is relatively low at US$272k, suggesting minimal alignment with common shareholders.
2025-12-07 15:16:00
Insiders at Q32 Bio Inc. sold shares earlier this year, missing out on a recent 52% stock gain. While an insider sold shares at around the current price of US$3.32, which is a cause for caution, there have been no insider share purchases in the last year. The article highlights that overall insider selling is substantial, making the company's insider ownership minimal, and suggests caution for investors.
2025-12-07 12:51:55
Q32 Bio shareholders saw a 52% stock gain, but company insiders missed out by selling shares earlier at US$2.86, lower than the current price of US$3.32. The recent sale by Jodie Morrison was the largest insider sale in the past year, totaling US$109k in shares. While insiders did not buy any shares, their minimal ownership of around US$272k may raise some caution for potential investors.
2025-12-06 04:51:55
This article provides live stock quotes and charts for Q32 Bio Inc. (QTTB), showing its current price, daily change, and historical performance. It also mentions the absence of analyst ratings and earnings information for the company, while promoting a stock analysis platform.
